Cystic fibrosis: Company urged to lower cost of life-changing drug
by BBC News | Health | UK Edition on April 21, 2018 at 10:02 am
Health ministers call on company to lower price of cystic fibrosis drug Orkambi so the NHS can afford it. (Source: BBC News | Health | UK Edition)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free. […]
Symdeko ™ Now Available from Fairview Specialty Pharmacy for Cystic...
by PRWeb: Medical Pharmaceuticals on April 12, 2018 at 11:00 pm
Fairview Specialty Pharmacy will now be distributing Symdeko™ (tezacaftor/ivacaftor and ivacaftor), which is approved for treatment of cystic fibrosis.(PRWeb April 13, 2018)Read the full story at http://www.prweb.com/releases/2018/04/prweb15409240.htm (Source: PRWeb: Medical Pharmaceuticals) […]
Cytochrome P450 3A4 induction: Lumacaftor versus ivacaftor?
by EurekAlert! - Biology on April 12, 2018 at 3:00 am
(Bentham Science Publishers) Cystic fibrosis is a disease caused by genetically defective CFTR proteins. The recent approval of lumacaftor combined with ivacaftor targets 70 percent of CF patients with F508del-CFTR. Unfortunately, our understanding of the way these drugs move (pharmacokinetics) and work (pharmacodynamics) in the human body is limited. For the first time, researchers have investigated potential cytochrome interactions of ivacaftor, its major metabolites, lumacaftor and tezacaftor which could result in reduced concentrations of the drug, causing reduced efficacy. (Source: EurekAlert! - Biology) […]
Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis
by HSMN NewsFeed on April 4, 2018 at 1:36 pm
CAMBRIDGE, Mass., April 4, 2018 -- (Healthcare Sales & Marketing Network) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic f... Biopharmaceuticals, FDA Proteostasis Therapeutics, transmembrane conductance regulator, cystic fibrosis (Source: HSMN NewsFeed) […]
UC scientist patents drug to treat dangerous infections
by bizjournals.com Health Care:Physician Practices headlines on April 3, 2018 at 3:32 pm
Daniel Hassett, a scientist with the University of Cincinnati College of Medicine, has been issued a patent for a drug that is could be used to treat lung infections in patients with cystic fibrosis or chronic obstructive pulmonary disease. The drug known as AB569 was developed in the lab of Hassett, a professor in the UC Department of Molecular Genetics, Biochemistry and Microbiology. It targets many antibiotic-resistant organisms that cause pulmonary infections in patients with cystic fibrosis… (Source: bizjournals.com Health Care:Physician Practices headlines) […]